GEDEON RICHTER
Celebrating 125 years

Transaction Conducted by a Person Discharging Managerial Responsibilities (PDMR)

Budapest, Hungary, 26 November 2026 – Gedeon Richter Plc. ("Richter" or the "Company") today announces that a transfer of ordinary shares held by Mr. Gábor Orbán, Chief Executive Officer of the Company, to a long-term investment account (TBSZ) was executed through sale and purchase transactions conducted on the Budapest Stock Exchange required for technical purposes. The received notification is hereby attached by the Company in accordance with Regulation 596/2014/EU and Decree No. 24/2008 (VIII. 15.) of the Minister of Finance. The transaction did not result in any change in the Chief Executive Officer's shareholding in Richter.

About Richter

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

For further information:

Investors:	Róbert Réthy, CFA	+36 20 342 2555
Media:	Zsuzsa Beke	+36 20 916 4507

Attachment

Notifications